

Prof. Dr. Mehmet BİLİCİ

Kişisel Bilgiler

İş Telefonu: [+90 442 344 7232](tel:+904423447232) Dahili: 7232

Web: <https://avesis.atauni.edu.tr/mbilici>

Posta Adresi: mbilici@atauni.edu.tr

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0003-1306-2238

Yoksis Araştırmacı ID: 111064

Araştırma Alanları

Sağlık Bilimleri

Verdiği Dersler

İÇ HASTALIKLARI ONKOLOJİ UZMANLIK DERSLERİ-2 YIL, Tıpta Uzmanlık, 2023 - 2024

İÇ HASTALIKLARI ONKOLOJİ UZMANLIK DERSLERİ-1 YIL, Tıpta Uzmanlık, 2023 - 2024

TIP FAKÜLTESİ 4. SINIF DERSLERİ, Lisans, 2023 - 2024

İÇ HASTALIKLARI ONKOLOJİ UZMANLIK DERSLERİ-4 YIL, Tıpta Uzmanlık, 2023 - 2024

TIP FAKÜLTESİ 6. SINIF DERSLERİ, Lisans, 2023 - 2024

İÇ HASTALIKLARI ONKOLOJİ UZMANLIK DERSLERİ-3 YIL, Tıpta Uzmanlık, 2023 - 2024

TIP FAKÜLTESİ 3. SINIF DERSLERİ, Lisans, 2023 - 2024

Deri Tümörleri, Lisans, 2022 - 2023

Kanserde Risk Faktörleri Tarama Yöntemleri ve Korunma, Lisans, 2020 - 2021

Kemoterapi Komplikasyonlarına Yaklaşım, Lisans, 2020 - 2021

Kemoterapinin Temel Prensipleri - 2, Lisans, 2020 - 2021

Kanserli Hastaya Yaklaşım, Lisans, 2020 - 2021

Onkolojide Tanı Yöntemleri, Lisans, 2020 - 2021

Kanserde erken tanı ve tarama, Lisans, 2020 - 2021

Onkolojik Aciller (A), Lisans, 2020 - 2021

Paraneoplastik Sendromlar (ÖnT), Lisans, 2020 - 2021

Kemoterapinin Temel Prensipleri - 1, Lisans, 2020 - 2021

Kanserde Ağrı Tedavisi, Lisans, 2020 - 2021

Memede Kitle, Lisans, 2020 - 2021

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- A novel prognostic biomarker in progression free survival for patients with cervical cancer, glucose to c-reactive protein ratio (GCR)**
Buyukbayram M. E., HANNARİCİ Z., TURHAN A., ÇAĞLAR A. A., ÇOBAN EŞDUR P., BİLİCİ M., TEKİN S. B., ERDEMCİ B.
BMC CANCER, cilt.24, sa.1, 2024 (SCI-Expanded)
- Pembrolizumab in HER2-Positive Gastric Cancer**
Janjigian Y. Y., Kawazoe A., Bai Y., Xu J., Lonardi S., Metges J. P., Yanez P., Wyrwicz L. S., Shen L., Ostapenko Y., et al.

NEW ENGLAND JOURNAL OF MEDICINE, 2024 (SCI-Expanded)

- III. **The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Regsturk-Lung study-Real-world data**
Cil T., Hacibekiroglu I., Uncu D., Isikdogan A., Ates O., Sendur M. A. N., Bilici M., Geredeli C., Turk H. M., Cicin I., et al.
JOURNAL OF CLINICAL ONCOLOGY, sa.16, 2024 (SCI-Expanded)
- IV. **Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results**
Janjigian Y. Y., Kawazoe A., Xu J., Lonardi S., Metges J., Wyrwicz L. S., Shen L., Ostapenko Y., Bilici M., Lowery M. A., et al.
JOURNAL OF CLINICAL ONCOLOGY, sa.3_SUPPL, ss.286, 2024 (SCI-Expanded)
- V. **The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker**
Buyukbayram M. E., Hannarici Z., Duzkopru Y., TURHAN A., ÇAĞLAR A. A., Esdur P. C., BİLİCİ M., TEKİN S. B., Yazılıtaş D.
Breast Cancer: Targets and Therapy, cilt.16, ss.329-339, 2024 (SCI-Expanded)
- VI. **Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study**
Janjigian Y. Y., Al-Batran S., Wainberg Z. A., Van Cutsem E., Molena D., Muro K., Hyung W. J., Wyrwicz L. S., Oh D., Omori T., et al.
JOURNAL OF CLINICAL ONCOLOGY, sa.3_SUPPL, ss.245-246, 2024 (SCI-Expanded)
- VII. **Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial**
Janjigian Y. Y., Kawazoe A., Bai Y., Xu J., Lonardi S., Metges J. P., Yanez P., Wyrwicz L. S., Shen L., Ostapenko Y., et al.
LANCET, cilt.402, sa.10418, ss.2197-2208, 2023 (SCI-Expanded)
- VIII. **The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer**
HANNARİCİ Z., Yılmaz A., Buyukbayram M. E., TURHAN A., ÇAĞLAR A. A., BİLİCİ M., TEKİN S. B.
FUTURE ONCOLOGY, cilt.19, sa.4, ss.315-325, 2023 (SCI-Expanded)
- IX. **Lipegfilgrastim may cause hyperleukocytosis**
HANNARİCİ Z., YILMAZ A., Buyukbayram M. E., TURHAN A., TEKİN S. B., BİLİCİ M.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.28, sa.8, ss.1902-1905, 2022 (SCI-Expanded)
- X. **Reply to John L. Frater's letter to the editor: Use of laboratory hematology data in melanoma research: comments on 'A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio'**
HANNARİCİ Z., YILMAZ A., Buyukbayram M. E., Tekin S. B., BİLİCİ M.
MELANOMA RESEARCH, cilt.32, sa.4, ss.302, 2022 (SCI-Expanded)
- XI. **The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib**
Yılmaz A., Şimşek M., Hannarici Z., Buyukbayram M. E., Bilici M., Tekin S. B.
FUTURE ONCOLOGY, cilt.17, sa.33, ss.4545-4559, 2021 (SCI-Expanded)
- XII. **The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study**
Akdeniz N., Kaplan M. A., Uncu D., İNANÇ M., Kaya S., DANE F., KÜÇÜKÖNER M., Demirci A., BİLİCİ M., Durnali A. G., et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, cilt.36, sa.6, ss.1311-1319, 2021 (SCI-Expanded)
- XIII. **Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study**
Koca S., Besiroglu M., Ozcelik M., Karaca M., BİLİCİ M., Hacıoglu B., DOĞU G. G., Kaplan N. B., Oruc Z., Aydin D., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.27, sa.3, ss.541-546, 2021 (SCI-Expanded)

- XIV. **Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience**
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., BİLİCİ M., ŞİMŞEK M., TEKİN S. B., Calikusu Z., et al.
CANCER INVESTIGATION, cilt.39, ss.473-481, 2021 (SCI-Expanded)
- XV. **Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia**
YILMAZ A., Mirili C., BİLİCİ M., TEKİN S. B.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.26, sa.7, ss.1791-1794, 2020 (SCI-Expanded)
- XVI. **The Significance of Controlling Nutritional Status (CONUT) Score as a Novel Prognostic Parameter in Small Cell Lung Cancer**
YILMAZ A., TEKİN S. B., BİLİCİ M., Yilmaz H.
LUNG, cilt.198, sa.4, ss.695-704, 2020 (SCI-Expanded)
- XVII. **The prognostic significance of hemoglobin-to-red cell distribution width ratio in muscle-invasive bladder cancer**
YILMAZ A., Yilmaz H., TEKİN S. B., BİLİCİ M.
BIOMARKERS IN MEDICINE, cilt.14, sa.9, ss.727-738, 2020 (SCI-Expanded)
- XVIII. **The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: a retrospective study**
YILMAZ A., Mirili C., TEKİN S. B., BİLİCİ M.
IRISH JOURNAL OF MEDICAL SCIENCE, cilt.189, sa.1, ss.91-102, 2020 (SCI-Expanded)
- XIX. **Colorectal cancer in Lynch syndrome associated with PMS2 and MSH6 mutations**
YILMAZ A., MİRİLİ C., BİLİCİ M., TEKİN S. B.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, cilt.35, sa.2, ss.351-353, 2020 (SCI-Expanded)
- XX. **Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study**
Kaplan M. A., Ozaydin S., Yerlikaya H., Karaagac M., GÜMÜŞ M., Cil T., Arslan U. Y., Ozdemir N., Sakin A., BİLİCİ M., et al.
ONCOLOGY RESEARCH AND TREATMENT, cilt.42, sa.10, ss.516-522, 2019 (SCI-Expanded)
- XXI. **A novel predictor in patients with gastrointestinal stromal tumors: Systemic immune-inflammation index (SII)**
YILMAZ A., MİRİLİ C., BİLİCİ M., TEKİN S. B.
JOURNAL OF BUON, cilt.24, sa.5, ss.2127-2135, 2019 (SCI-Expanded)
- XXII. **Creatinine kinase elevation and peripheral neuropathy during nivolumab treatment of a patient with metastatic renal cell carcinoma**
ŞİMŞEK M., BİLİCİ M., TEKİN S. B.
INDIAN JOURNAL OF CANCER, cilt.55, sa.4, ss.413-414, 2018 (SCI-Expanded)
- XXIII. **Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)**
Inal A., Kodaz H., Odabas H., Duran A. O., Seker M. M., Inanc M., ELKIRAN E. T., Gunaydin Y., Menekse S., Topcu T. O., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, sa.3, ss.578-582, 2018 (SCI-Expanded)
- XXIV. **Determination of Retinol and Beta-Carotene after Beta-Carotene Administration in Patients with Stomach Cancer via HPLC-DAD Method in Human Plasma**
DEMİRKAYA MİLOĞLU F., ŞENOL O., KADIOĞLU Y., BİLİCİ M.
LATIN AMERICAN JOURNAL OF PHARMACY, cilt.36, sa.4, ss.740-749, 2017 (SCI-Expanded)
- XXV. **EARLY ONSET OF RADIATION INDUCED SARCOMA: A CASE REPORT AND REVIEW OF THE LITERATURE**
YILDIRIM N., ŞİMŞEK M., TÜRKELİ M., BİLİCİ M., KIZILTUNÇ ÖZMEN H.
Acta Medica Mediterranea, ss.565-568, 2017 (SCI-Expanded)

- XXVI. **MULTICENTRIC BONE INVOLVEMENT AND COMPLETE RESPONSE TO CHEMOTHERAPY: A CASE REPORT**
ŞİMŞEK M., TÜRKELİ M., ALDEMİR M. N., YILDIRIM N., TEKİN S. B., BİLİCİ M.
ACTA MEDICA MEDITERRANEA, cilt.32, sa.1, ss.163-166, 2016 (SCI-Expanded)
- XXVII. **Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology)**
Kaplan M. A., Arslan U. Y., Isikdogan A., DANE F., Oksuzoglu B., İNANÇ M., Akman T., KÜÇÜKÖNER M., Cinkir H. Y., Rzaade R., et al.
BREAST CARE, cilt.11, sa.4, ss.248-252, 2016 (SCI-Expanded)
- XXVIII. **EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN ELDERLY PATIENTS WITH METASTATIC GASTRIC CANCER**
TÜRKELİ M., ALDEMİR M. N., ŞİMŞEK M., YILDIRIM N., BİLİCİ M., Cayir K., TEKİN S. B., YETİMOĞLU H.
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, cilt.19, sa.1, ss.27-34, 2016 (SCI-Expanded)
- XXIX. **Pathologic and Clinical Characteristics of Elderly Patients With Breast Cancer: A Retrospective Analysis of a Multicenter Study (Anatolian Society of Medical Oncology)**
Inal A., Akman T., Yaman S., Ozturk S. C., Geredeli C., BİLİCİ M., İNANÇ M., Harputoglu H., Demirci U., Balakan O., et al.
INTERNATIONAL SURGERY, cilt.99, sa.1, ss.2-7, 2014 (SCI-Expanded)
- XXX. **Levels of vitamin K3 in healthy volunteers and in patients with different types of stomach cancer after a single vitamin K3 administration**
Demirkaya-Miloglu F., KADIOĞLU Y., BİLİCİ M., TEKİN S. B., OZTURK M.
Journal of Liquid Chromatography and Related Technologies, cilt.36, sa.11, ss.1467-1477, 2013 (SCI-Expanded)
- XXXI. **Is lymph node ratio prognostic factor for survival in elderly patients with node positive breast cancer? The Anatolian Society of Medical Oncology**
Inal A., Akman T., Yaman S., Ozturk S. C., Geredeli C., BİLİCİ M., İNANÇ M., Harputoglu H., Demirci U., Suner A., et al.
ANNALI ITALIANI DI CHIRURGIA, cilt.84, sa.2, ss.143-148, 2013 (SCI-Expanded)
- XXXII. **Investigation of ErbB-2 Overexpression on Patients with Gastric Cancer in Eastern Anatolia of Turkey**
Emre H., TEKİN S. B., DOĞAN H., ÇAYIR K., BİLİCİ M., ŞİPAL S., Pirim I.
TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.24, sa.3, ss.211-217, 2013 (SCI-Expanded)
- XXXIII. **Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy**
Kandaz M., Ertekin M. V., BİLİCİ M.
TUMORI, cilt.98, sa.4, ss.445-450, 2012 (SCI-Expanded)
- XXXIV. **The evaluation of the results of adjuvant chemoradiotherapy in patients with gastric cancer: results from a single center in eastern Anatolia**
BİLİCİ M., TEKİN S. B., KANDAZ M., ÇAYIR K., ERTEKİN M. V., Ozmen H.
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.42, sa.2, ss.329-336, 2012 (SCI-Expanded)
- XXXV. **Effect of mirtazapine on MNNG-induced gastric adenocarcinoma in rats.**
Bilici M., ÇAYIR K., Tekin S. B., GUNDOĞDU C., Albayrak A., SULEYMAN B., ÖZOĞUL B., Erdemci B., SULEYMAN H.
Asian Pacific journal of cancer prevention : APJCP, cilt.13, ss.4897-900, 2012 (SCI-Expanded)
- XXXVI. **Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)**
Kaplan M. A., Isikdogan A., Koca D., Kucukoner M., Gumusay O., Yildiz R., Dayan A., Demir L., Geredeli C., Kocer M., et al.
ONCOLOGY, cilt.83, sa.3, ss.141-150, 2012 (SCI-Expanded)
- XXXVII. **AN UNUSUAL CAUSE OF CIRRHOSIS: ALVEOLAR ECHINOCOCCOSIS**
YILMAZ Ö., DURSUN H., ALBAYRAK F., UYANIK A., KELEŞ M., BİLİCİ M.
NOBEL MEDICUS, cilt.7, sa.1, ss.106-108, 2011 (SCI-Expanded)
- XXXVIII. **Relation of antiulcer effect of progesterone resulting from follicle stimulating hormone inhibition with gastric cyclooxygenase levels in female rats**
Karaca M., BÖREKÇİ B., KUMTEPE Y., SALMAN S., HACİMÜFTÜOĞLU A., GÜLABOĞLU M., BİLİCİ M., DURSUN H.

- Asian Journal of Chemistry, cilt.22, sa.5, ss.3761-3770, 2010 (SCI-Expanded)
- XXXIX. **Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers.**
SULEYMAN H., Albayrak A., Bilici M., Cadirci E., Halici Z.
Inflammation, cilt.33, ss.224-34, 2010 (SCI-Expanded)
- XL. **Distribution of HLA Tissue Groups in Patients with Gastric Cancer.**
BİLİCİ M., Okcu N., CAYIR K., PIRIM I., TEKİN S., GÜNDOĞDU C.
The Eurasian journal of medicine, cilt.42, ss.9-11, 2010 (SCI-Expanded)
- XLI. **COX-2 Expression in Gastric Cancer**
Bekdemir H., Tekin S. B., BİLİCİ M., Cayir K., GÜNDOĞDU C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, cilt.20, sa.1, ss.34-41, 2010 (SCI-Expanded)
- XLII. **Relation of adrenergic receptors, which have roles in gastroprotective and anti-inflammatory effect of adrenal gland hormones, with cyclooxygenase enzyme levels in rats**
SULEYMAN H., DURSUN H., BİLİCİ M., ÇADIRCI E., HALICI Z., GÜLABOĞLU M., ALBAYRAK F.
Journal of Physiology and Pharmacology, cilt.60, sa.4, ss.129-134, 2009 (SCI-Expanded)
- XLIII. **Analysis of HLA class I and II alleles regarding to lymph node and distant metastasis in patients with non-small cell lung cancer**
Bulut I., Meral M., Kaynar H., Pirim I., BİLİCİ M., Gorguner M.
LUNG CANCER, cilt.66, sa.2, ss.231-236, 2009 (SCI-Expanded)
- XLIV. **Protective Effect of Mirtazapine on Indomethacin-Induced Ulcer in Rats and Its Relationship with Oxidant and Antioxidant Parameters**
Bilici M., ÖZTÜRK C., DURSUN H., ALBAYRAK F., SAĞLAM M. B., Uyanik A., GÜLABOĞLU M., Tekin S. B.
DIGESTIVE DISEASES AND SCIENCES, cilt.54, sa.9, ss.1868-1875, 2009 (SCI-Expanded)
- XLV. **A case of ichthyosiform sarcoidosis with unusual localization**
TEKİN S. B., Cayir K., BİLİCİ M., ŞİPAL S., ATASOY M., TÜRKELİ M.
CENTRAL EUROPEAN JOURNAL OF MEDICINE, cilt.4, sa.3, ss.388-390, 2009 (SCI-Expanded)
- XLVI. **Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue**
DURSUN H., BİLİCİ M., ALBAYRAK F., Ozturk C., SAĞLAM M., ALP H., Suleyman H.
BMC GASTROENTEROLOGY, cilt.9, 2009 (SCI-Expanded)
- XLVII. **Long-term treatments with low- and high dose olanzapine change hepatocyte numbers in rats. A stereological and histopathological study.**
ODACI E., Bilen H., Hacimuftuoglu A., Keles O. N., CAN I., Bilici M.
Archives of medical research, cilt.40, ss.139-45, 2009 (SCI-Expanded)
- XLVIII. **STEREOLOGICAL AND HISTOLOGICAL ANALYSIS OF THYROID IN 20 DAYS RAT FOETUSES**
Altunkaynak M. E., Altunkaynak B. Z., ÜNAL D., Bilici M., CAN İ., VURALER Ö., ÜNAL B.
IUBMB LIFE, cilt.61, sa.3, ss.330-331, 2009 (SCI-Expanded)
- XLIX. **Serum Adiponectin Levels in Patients with Esophageal Cancer**
YILDIRIM A., BİLİCİ M., Cayir K., Yanmaz V., YILDIRIM S., TEKİN S. B.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.2, ss.92-96, 2009 (SCI-Expanded)
- L. **Antioxidant enzyme activities and lipid peroxidation levels in erythrocytes of patients with oesophageal and gastric cancer**
Dursun H., Bilici M., Uyanik A., Okcu N., AKYÜZ M.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, cilt.34, sa.2, ss.193-199, 2006 (SCI-Expanded)
- LI. **Morphological alterations produced by zinc deficiency in rat sciatic nerve: A histological, electron microscopic, and stereological study**
ÜNAL B., Tan H., Orbak Z., Kiki I., Bilici M., BİLİCİ N., ASLAN H., KAPLAN S.
BRAIN RESEARCH, cilt.1048, ss.228-234, 2005 (SCI-Expanded)

- I. **Inflammatory parameters in NSCLC with driver mutation**
Buyukbayram M. E., Hannarici Z., Yılmaz A., TURHAN A., ÇAĞLAR A. A., ÇOBAN EŞDUR P., BİLİCİ M., TEKİN S. B.
LUNG CANCER MANAGEMENT, cilt.13, sa.1, 2024 (ESCI)
- II. **Clinical significance of inflammatory indexes in patients with epithelial ovarian cancer**
YILMAZ A., TEKİN S. B., BİLİCİ M., yılmaz h.
ACTA ONCOLOGICA TURCICA, 2020 (Hakemli Dergi)
- III. **Survival Analysis and Prognostic Factors in Prostate Cancer Patients: A Single Center Experience in Eastern Anatolia**
YILMAZ A., BİLİCİ M., TEKİN S. B.
Dicle Tıp Dergisi, 2020 (Hakemli Dergi)
- IV. **Servikal Kanser Hastalarının Uzun Dönem Sonuçları: Doğu Anadolu Tek Merkez Deneyimi / Long-Term Follow-Up Outcomes of Cervical Cancer Patients: A Single Center Experience from the East Anatolian Region of Turkey**
MİRİLİ C., YILMAZ A., BİLİCİ M., TEKİN S. B.
Dicle Tıp Dergisi, cilt.46, sa.4, ss.857-865, 2019 (Hakemli Dergi)
- V. **Clinical results and importance of next-generation sequencing (NGS) in detecting targeted mutations in the treatment of metastatic Lung Cancer: Single center initial results**
Mirili C., Kahraman Ç., Yılmaz A., Bilici M., Tekin S. B., Tatar A., Yakar Ö., Ercoşkun P.
Medical Science and Discovery, cilt.6, sa.12, ss.327-332, 2019 (Hakemli Dergi)
- VI. **Rare Breast Malignancies**
Yildirim N., Aldemir M. N., ŞİMŞEK M., BİLİCİ M., TEKİN S. B.
MEDICAL JOURNAL OF BAKIRKOY, cilt.15, sa.3, ss.232-239, 2019 (ESCI)
- VII. **Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers**
Yildirim N., ŞİMŞEK M., Aldemir M. N., BİLİCİ M., TEKİN S. B.
EURASIAN JOURNAL OF MEDICINE, cilt.51, sa.2, ss.154-159, 2019 (ESCI)
- VIII. **Immunological Agents Used in Cancer Treatment**
ŞİMŞEK M., TEKİN S. B., BİLİCİ M.
EURASIAN JOURNAL OF MEDICINE, cilt.51, sa.1, ss.90-94, 2019 (ESCI)
- IX. **Gastrointestinal Stromal Tumors: A Single Center Experience**
Yildirim N., ŞİMŞEK M., Aldemir M. N., BİLİCİ M., Basol Tekin S.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.32, sa.1, ss.19-24, 2017 (ESCI)
- X. **Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years' Experience**
Türkeli M., Simsek M., Aldemir M. N., Yildirim N., ÇANKAYA E., ERDEMCİ B., BİLİCİ M., TEKİN S. B., Arslan S., KORKUT E.
EURASIAN JOURNAL OF MEDICINE, cilt.48, sa.1, ss.33-36, 2016 (ESCI)
- XI. **Remisyonda ve Takipte Kanser Hastasında Beslenme Nutrition of Cancer Patient in Remission and Follow Up Periods**
BİLİCİ M.
Türkiye Klinikleri Journal of Medical Oncology Special Topics, 2016 (Hakemsiz Dergi)
- XII. **Tiroit Kanserinde Tıbbi Tedavi**
BİLİCİ M., TEKİN S. B.
Türkiye Klinikleri J Gen Surg-Special Topics, 2016 (Hakemsiz Dergi)
- XIII. **Are We Late at the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients 11 Years Experience**
TÜRKEİ M., ŞİMŞEK M., ALDEMİR M. N., YILDIRIM N., ÇANKAYA E., ERDEMCİ B., BİLİCİ M., TEKİN S. B., ARSLAN Ş., KORKUT E.
Eurasian Journal of Medicine, 2015 (Scopus)
- XIV. **Coping anxiety and depression in Turkish patients with cancer**
YILMAZ KARABULUTLU E., BİLİCİ M., ÇAYIR K., TEKİN S. B., KANTARCI R.

- European Journal of General Medicine, cilt.7, ss.296-302, 2010 (Hakemli Dergi)
- XV. **The Levels of Serum C-Reactive Protein, Beta 2 Microglobulin, Ferritin, Lactate Dehydrogenase and Some Specific Proteins in Patients with Non-Hodgkin's Lymphoma Before and After Treatment**
YILDIRIM R., GÜNDOĞDU M., ERDEM F., KİKİ İ., BİLİCİ M.
EURASIAN JOURNAL OF MEDICINE, cilt.41, sa.3, ss.165-168, 2009 (Hakemli Dergi)
- XVI. **Stereological Evaluation of Tumor Regression Rates in Lung Cancer Using CT Via the Cavalieri Method**
AKGÜN M., KANTARCI A., Cayir K., BAYRAKTUTAN Ü., Doganay S., ARAZ Ö., Altunkaynak E., BİLİCİ M., Unal B., Gorguner M.
EURASIAN JOURNAL OF MEDICINE, cilt.40, sa.3, ss.109-114, 2008 (ESCI)
- XVII. **A GIANT HEMANGIOMA WITH 35 CM IN DIAMETER: A CASE REPORT**
YILMAZ Ö., BİLİCİ M., ÇAYIR K.
Eurasian J Med, cilt.38, ss.57-59, 2006 (Hakemli Dergi)
- XVIII. **Effect of Carotid Stenosis on the Development of Subarachnoid Hemorrhage Eksperimental Study**
ATALAY C., BAYRAM E., AYDIN M. D., BİLİCİ M., OKUMUŞ Z., GÜNDOĞDU C.
Turkish Journal Of Medical Sciences, cilt.35, ss.379-383, 2005 (Scopus)

Kitap & Kitap Bölümleri

- I. **Jinekolojik Tümörler El Kitabı Tanı Tedavi Takip Tedavi Algoritmalarının Oluşturulması**
BİLİCİ M., AYDINER A., BİLİCİ A., KİZİR A., Ağaoğlu A., SEZER Y. A., sevinç a., BAKIR B., Oyan Uluç B., Öven Ustaalioğlu B., et al.
Nobel Tıp Kitapevleri, İstanbul, 2016

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer: subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study**
Janjigian Y. Y., Al-Batran S., Wainberg Z. A., Van Cutsem E., Molena D., Muro K., Hyung W. J., Wyrwicz L., Oh D., Omori T., et al.
Annual Meeting of the Society-of-Surgical-Oncology (SSO), Georgia, Amerika Birleşik Devletleri, 20 - 23 Mart 2024
- II. **Triple-Negatif Meme Kanseri Hastalarının Retrospektif İncelenmesi**
Şimşek M., Altunok M., Bilici M., Tekin S. B.
2. Uluslararası Sağlık Araştırmaları Kongresi, 12 Ekim 2022
- III. **Nadir Görülen Anorektal Malign Melanom: Üç Olgu Sunumu**
ALDEMİR M. N., TÜRKELİ M., ŞİMŞEK M., YILDIRIM N., ERDEMCİ B., BİLİCİ M., TEKİN S. B.
2. İmmuno-Onkoloji ve Hedefe Yönelik Kanser Tedavileri Kongresi, Antalya, Türkiye, 13 - 17 Mayıs 2015

Metrikler

Yayın: 101
Atf (WoS): 668
Atf (Scopus): 864
H-İndeks (WoS): 13
H-İndeks (Scopus): 15